Upadacitinib as Rescue Therapy for the Treatment of Acute Severe Colitis in an Acute Care Setting.

Abstract

Inflammatory bowel disease is a chronic, relapsing, and remitting inflammatory disorder that despite advances in medical therapy often requires hospitalization for treatment of acute flares with intravenous corticosteroids. Many patients will not respond to corticosteroids and require infliximab or cyclosporine as rescue therapy. If medical therapy fails, definitive surgical management is required. Recently, Janus Kinase inhibitors, including upadacitinib, have been proposed as an alternative rescue therapy. We hypothesized that upadacitinib may be effective in treating acute severe colitis. A retrospective review of 12 inflammatory bowel disease patients admitted for acute severe colitis who received upadacitinib induction therapy was performed. The rates of surgery, repeat or prolonged steroid use, and re-admission within 90days of index hospitalization were measured. The need for re-induction with upadacitinib, change in medical therapy, rates of clinical remission, change in 6-point partial Mayo score, and laboratory markers of inflammation were measured as secondary outcomes. Five patients met the primary composite endpoint including four patients requiring surgery and one additional patient being unable to withdraw steroids within 90days of hospital discharge. One patient required re-induction with upadacitinib within 90days and no patients required change in medical therapy within 90days. Most patients who did not undergo surgery were in clinical remission within 90days and showed clinical improvement with decreased 6-point partial Mayo scores. Upadacitinib may be effective salvage therapy for acute severe colitis, but larger controlled trials are required to validate these results.